An interventional study of 3M™ V.A.C.® Peel and Place Dressing in Wound, sponsored by Solventum US LLC. Recruiting at 3 sites in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Solventum US LLC · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this clinical study is to obtain post-market safety and efficacy data when the V.A.C.® Peel and Place dressing is used in conjunction with 3M™ V.A.C.® Therapy.
This is a prospective, post-market, multi-center, single-arm study. A target of 90 enrolled Subjects with 1 enrolled study wound per Subject is planned for this study, including 60 open wounds (10 for each type of open wound) and 30 closed or covered wounds (10 for each type of closed/covered wound). The entire duration of the study is expected to last approximately 2 years. Individual Subject participation is expected to last up to 20 days, including a screening period lasting up to 5 days, the day of initial treatment, dressing change visits as clinically appropriate but no more than 7 days from dressing application, and an end-of-treatment (EOT)/end-of-study (EOS) visit between Day 7 and Day 14 after the initial dressing application.
2,220 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.
This study's planned enrollment of 90 is above the median of 70 across 1,425 interventional studies indexed under Wounds and Injuries.
Browse Wounds and Injuries studies →Solventum US LLC is the lead sponsor of 64 studies on the registry; 2 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has a wound deemed appropriate for treatment with a V.A.C.® Peel and Place dressing (used in conjunction with 3M™ V.A.C.® Therapy), according to the instructions for use for the dressing, including the following wound types:
Exclusion Criteria:
Subject is pregnant or lactating prior to application of the initial dressing. *
*Women who have had surgical sterilization by a medically accepted method (ie, tubal ligation, hysterectomy, or oophorectomy) or are , defined as not having menstruation for > 12 months will not be required to undergo pregnancy testing.
In the case of a lower extremity wound, the Subject has one of the following:
Individual wounds are to be excluded from the study if they meet any of the following criteria
The wound received, within 30 days before initiating V.A.C.® Therapy, treatment with any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3M™ V.A.C.® Peel and Place Dressing used in conjunction with 3M™ V.A.C.® Therapy
Device: 3M™ V.A.C.® Peel and Place Dressing
Application of 3M™ V.A.C.® Peel and Place Dressing used in conjunction with 3M™ V.A.C.® Therapy
Incidence of (ADEs)
The incidence of adverse device effects (ADEs)
Time frame: 14 days
Percentage of closed surgical incisions and skin flaps that remain closed
The percentage of closed surgical incisions and skin flaps that remain closed throughout treatment
Time frame: 14 days
Percentage of skin grafts with ≥ 90% graft take
The percentage of skin grafts with ≥ 90% graft take at the end of treatment
Time frame: 14 days
Percentage of open wounds with evidence of healing
The percentage of open wounds with evidence of healing, as evidenced by any of the following: * decrease in total wound area (cm2) from baseline to the end of treatment, * decrease in total wound volume (cm3) from baseline to the end of treatment, * decrease in average wound depth from baseline to the end of treatment, * increase in the percentage of the wound with red color composition (signifying healthy, viable tissue), from baseline to the end of treatment, * improved score for exudate amount from the first dressing change to the end of treatment * improved score for peripheral tissue edema from baseline to the end of treatment * new epithelialization from baseline to the end of treatment, or * wound is deemed ready for closure (via delayed primary closure, graft, flap or allowed to epithelialize) at any time from baseline to the end of treatment
Time frame: 14 days
Overall rate of wound healing for both open wounds and closed/covered wounds
The overall rate of wound healing for both open wounds and closed/covered wounds, as evidenced by the aforementioned criteria
Time frame: 14 days
Pain score associated with dressing removal
The pain score associated with dressing removal (ie, during dressing changes and at final dressing removal) - Subject-reported and based on the highest level of perceived pain. Whereby a score of 0 is indicative of "no pain" and a score of 10 indicates the "worst pain possible".
Time frame: 14 days
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.
Of 53 industry-sponsored interventional studies with no phase under Wounds and Injuries, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 23 months is close to that.
Counting every sponsor, half of 599 studies reached it within 24 months; a quarter within 9 and three quarters within 48.
Wounds and Injuries covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.